Currently, several antiviral drugs (e.g.,, remdesivir, bemcentinib, and lopinavir with ritonavir), immune modulators (e.g., azithromycin, brensocatib, anakinra and canakinumab, interferon beta, convalescent plasma, corticosteroids, sarilumab and tocilizumab) are recommended against COVID-19 (Connelly, 2020), and their usage mainly depends on patient’s symptoms, while remdesivir is approved by the FDA for treatment of COVID-19 (Beigel et al., 2020). Here, IFNB1 is linked to COVID-19.